In addition, NOX-E36 showed excellent bioavailability after subcutaneous administration. This fact should make it possible to achieve a dosing regimen with at least once weekly administration. Final results and analysis for this phase I trial are expected by early 2010.

The results of this phase I study will be instrumental in the design of the upcoming multiple dose studies in healthy volunteers and non-insulin dependent diabetic patients with multiple complications. The recruitment phase for these studies will begin in early 2010.

Dr Frank Morich, CEO of NOXXON Pharma AG, commented: The preliminary results of this phase I study are impressive and show that Spiegelmers?® have the potential to become a novel class of broadly applicable therapeutic agents addressing large areas of unmet medical need. They also indicate that Spiegelmers?® can be applied in convenient dosing regimens. In the meantime our other drug candidates are advancing rapidly towards clinical development.

Source: NOXXON Pharma AG